The Globe and Mail reports in its Tuesday edition that the latest pullback in pot stocks may represent a buying opportunity. The Globe's Brenda Bouw writes that shares of Canopy Growth, Aurora Cannabis, Organigram Holdings, CanniMed Therapeutics and Emerald Health Therapeutics are down by between about 10 per cent to 30 per cent since April 12, the day before Ottawa tabled its legislation with a self-imposed deadline to legalize pot by July 1, 2018. Shares of Canopy, Canada's largest producer, are down 15 per cent since April 12 and have lost about half their value since they hit a high of $17.86 in November. Still, the stock is up almost 240 per cent over the past year. Shares of Aphria, which hit a high of $8.77 on April 11, have dropped by almost 30 per cent. Aphria insiders appear to view the pullback as a buying opportunity. At least three insiders have been buying shares in the public market of late. The Horizons Medical Marijuana Life Sciences ETF, which went public on April 5, recently started trading below its $10 initial public offering price, moving further away from its high of $12.40 on April 11. PI Financial analyst Jason Zandberg says, "I do see this as a buying opportunity."